IntroductionCancer chemotherapy resistance is the main reason for failureof chemotherapeutic response in patients. Chemotherapy resistance can presentbefore initiating chemotherapy (primary, innate or intrinsic resistance), orduring chemotherapy (Aquired or extrinsic resistance) 1,2,7. Also,chemotherapy failure can arise from host-related factors 1. However, researchersfocus on understanding tumor-related factors that caused most of thechemotherapy failure or resistance 1. For example, treatment of Hepatocelularcarcinoma (HCC), multiple myloma, and breast cancer is difficult due to geneticor epigenetic changes in cancer cells leading to marked chemotherapy resistance4,6,7. Resistance mechanisms are numerous and complex 2.
The majormechanism involved in chemotherapy resistance is the over expression ofATP-binding cassette (ABC) transporters, which can increase efflux of drugsfrom cancer cells, thereby decreasing intracellular drug concentration 3.Chemotherapy resistance can be divided into three divisions: (1) Macroscopic(systemic) resistance host–related factors, (2) Microscopic (local)resistance tumor related factors and (3) Mesoscopic (physical, mechanical) or(regional) resistance tumor—host interacting factors 1. Macroscopic (systemic) resistance host–related factorsFor an effective chemotherapy, a chemotherapeutic agent mustreach the tumor 1. Therefore, the pharmacokinetics are an importanthost-related factors which have an influence in the chemotherapy efficacy 1.If the drug doesn’t reach its target in a sufficient level, we call this “PharmacokineticResistance”1.
AbsorptionOral administration of the chemotherapeutic agent is betterthan intravenous administration, because: (1) There is no hospitalizationrequired, (2) it prolongs it’s time to clearance, which increase antitumoractivity, (3) it decrease drug toxicity, (4) it enhance patient compliance 1.However, to maintain a sufficient amount of orally administeredchemotherapeutics, several factors should be taken into consideration 1:1. P-gp (Permeability glycoprotein)P-gp is located in the gastrointestinal tract, including thesmall intestine where absorption of most anticancer drugs takes place 1. P-gpoverexpression can occur due to genetic polymorphism, pathological conditionand concomitant administration of some anticancer drugs 1. This result indecreased bioavailability of antineoplastic agent 1.2.
FoodFood can affect absorption and bioavailability ofantineoplastic agent 1. For example, a high-fat meal decreases the rate ofabsorption of Topotecan, but it does affect its extent of absorption 1. StJohn’s wort, reduces the efficacy of some antineoplastic agent by inducing theexpression of Pregnane X receptor, a xenobiotic or detoxification sensor 1.Grapefruit juice, decrease the metabolism of antineoplastic agent in theintestine by reducing the presence of CYP3A4, a metabolising enzyme 1.DistributionThe distribution of the drug between plasma and tissuesdepends on several factors 1. Some of them include:1.
GenderFor example, metronidazole has a low volume of distributionin women 1.2. WeightDose adjustment is needed in cancer pateints as they loseweight because of tumor progression 1.3. Plasma ProteinsChanges in the plasma concentration of albumin or Alpha-1-acidglycoprotein result in variable anticancer activity due to binding of someanticancer agents to these proteins 1.4. CircadianrhythmThe best time for administration of anticancer agent is atnight, because the basal metabolic rate is increased at night.
This result inincrease activity of anticancer agents since they act against highly proliferatingcells, mainly cancer cells 1.MetabolismDrug metabolism is different from anabolism and catabolism1. Its main role is detoxification or activation of drugs 1.
· CYP450 (Cytochrome P450) Enzymes, can activate someantineoplastic agent, as well as inactivate them 1. Overexpression of CYP450in cancer patients might lead to resistance due to the rapid inactivation of antineoplasticagent 1.· GSTs (Glutathione–S–Transferases), overexpression ofGSTs in cancer patients might lead to resistance 1.
It is involved in drug inactivationand apoptosis suppression 1.· Extrahepatic metabolism: anticancer agent inactivationcan occur in the lung, gut, kidney, urinary bladder and skin 1.ExcretionExcretion of anticancer agent occur through two main routes:biliary and renal excretion 1.· Biliary or bile duct excretion: Overexpression of ABCincrease the biliary excretion of anticancer agent 1.
· Renal excretion: increase in the glomerular filtrationrate (GFR) reduces availability of anticancer drug 1.Combination TherapyAdministration of a single chemotherapeutic agent is noteffective. Since, high concentration of the agent is needed, plus it causes moretoxicity, increase the likelihood of resistance and attack only singlepopulation of tumor (a tumor consists of a heterogeneous population) 1.However, using a combination of chemotheraputics agents is effective. Since, itdecreases the required concentration for each agent, decreases the sideeffects, decreases the likelihood of resistance and attack several populationof the tumor 1. Microscopic (local) resistance tumor related factorsIneffective chemotherapy can occur due to failure at thetumor site 1. This happens by several mechanisms. Some of them are:Evolutionary resistanceAlso called acquired resistance, extrinsic resistance, activeresistance, or biochemical resistance 1.
Evolutionary resistance could occureither through manipulating drug resident time inside the cell and/or modifyingits site of action 1.1. Alteration of drug residency in cancer cellsProteins are the main reason for altering drug residency incancer cell, including:· P-gp: also called multidrug resistanceprotein 1 (MDR1) or ATP-binding cassette sub-family B member 1 (ABCB1) orcluster of differentiation 243 (CD243) 1. P-gp also induces expression of CYP3A4 that in turn maydeactivate some antineoplastic agent 1. Expression of P-gp fluctuates withincreased expression level in untreated cancer into higher level upon relapseafter chemotherapy and undetectable or decreased level in the expression indrug sensitive tumors 1.· MRPs (Multidrug resistance-associated protein): The MRP family consists of the fourisoforms MRP1, MRP2, MRP3 and MRP4 1 . MRPs are similar to P-gp in that theyare (1) capable of lowering intracellular drug levels and (2) ATP-dependent 1.· MXR (Mitoxantrone resistance protein): also called Multixenobiotic resistance protein, BCRP, ABCP and ABCG2, is one member ofthe ABC-superfamily that plays a role in trafficking biological moleculesacross cell membranes 1.
Expression of MXR can be an alternative strategy ofresistance if cancer cells lack p-gp and MRP 1.2. Alteration of drug targetWhen the drug reaches its target, another mechanism ofresistance could be evolved somatically 1. Examples, which explain thismechanism of resistance, is:· Genomic amplification of the DHFR gene is reflected byextra copies of DHFR 1.
· It has been postulated that one mechanism ofresistance is the gain of extra copies of thymidylate synthetase genes 1.MicroenvironmentalresistanceCancer cells have different microenvironment than normalcells. For example, they have a unique pH gradient; it is more acidic extracellularlyand more basic intracellularly 1. Cancer cells are able to blunt and suppressthe immune system, inhibit the growth of normal cells and disturb drug partitioningdue their special microenvironment 1. There are several components of thetumor microenvironment that contribute to drug disability 1. Some of theminclude:· pHAnticancer agent undergo “iontrapping mechanism”, where weakly basic anticancer agents partitioning tocancer cells are decreased due to its ionization at the interstitial fluid and theirincorporation into the lysosomes after they cross the plasma membrane 1. And,where weakly acidic anticancer agents partitioning to cancer cells are increasedand rendered after they cross the plasma membrane, slightly prevented from reachingthe target site 1.
· OxygenHypoxia causes chemotherapy resistance by eliminating the presence offree radicals, which is important to initiate apoptosis of cancer cells 1.· GlucoseHyperglycemia may have influence inthe efficacy of chemotherapy 5. Mesoscopic (physical, mechanical) or (regional) resistancetumor—host interacting factorsBlood vessel morphology and blood viscosity at tumor siteaffect chemotherapy efficacy 1. Increase vascular resistance and bloodviscosity results in a decrease of the amount of anticancer agent reachingtheir target site and vice versa 1.